MicroRNA Expression in Malignant Pleural Mesothelioma and Asbestosis: A Pilot Study. (3rd July 2017)

• Record Type: Journal Article
• Authors: Mozzoni, Paola; Ampollini, Luca; Goldoni, Matteo; Alinovi, Rossella; Tiseo, Marcello; Gnetti, Letizia; Carbognani, Paolo; Rusca, Michele; Mutti, Antonio; Percesepe, Antonio; Corradi, Massimo
• Other Names: González Alvaro Academic Editor.
• Is Part Of: Disease markers. Volume 2017(2017)
• Publication Date: 2017-07-03
• Subjects: Diagnosis -- Periodicals; Biochemical markers -- Periodicals; Pathology -- Periodicals; 616
• DOI: 10.1155/2017/9645940
• Languages: English
• ISSNs: 0278-0240

Abstract

Abstract : Background . The identification of diagnostic/prognostic biomarkers for asbestos-related diseases is relevant for early diagnosis and patient survival and may contribute to understanding the molecular mechanisms underlying the disease development and progression. Aims . To identify a pattern of miRNAs as possible diagnostic biomarkers for patients with malignant pleural mesothelioma (MPM) and asbestosis (ASB) and as prognostic biomarkers for MPM patients. Methods . miRNA-16, miRNA-17, miRNA-126, and miRNA-486 were quantified in plasma and formalin-fixed paraffin-embedded samples to evaluate their diagnostic and prognostic roles compared to patients with other noncancerous pulmonary diseases (controls). Results. The expression of all the miRNAs was significantly lower in patients with MPM and ASB than that in controls. miRNA-16, miRNA-17, and miRNA-486 in plasma and tissue of MPM patients were significantly correlated. Furthermore, the expression of miRNA-16 in plasma and tissue, and miRNA-486 only in tissue, was positively related with cumulative survival in MPM patients. Conclusions . All the miRNA levels were decreased in patients with MPM or ASB, supporting the role of circulating miRNAs as a potential tool for diseases associated with exposure to asbestos fibers. miRNA-16 was directly related to MPM patient prognosis, suggesting its possible use as a prognostic marker in MPM patients.